JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Correction for Nunn, J Nucl Med 49 (6) 28N-32N.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Journal of Nuclear Medicine Vol. 49 No. 8 38N
© 2008 by Society of Nuclear Medicine

Correction

Correction

In the article "Imaging biomarkers, an industry perspective," in the June issue of Newsline (2008;49:29N), Herceptin was incorrectly described as approved for neoadjuvant therapy. Herceptin has been approved by the U.S. Food and Drug Administration for use in both the metastatic and adjuvant settings for women with HER2-positive breast cancer. The editor of Newsline thanks Jonathan R. Potter, senior vice president, Fleishman-Hillard International Communications (New York, NY), for submitting this correction.





This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE